// App-Quantinova.ai

772TiP : A phase 1/2 study of ramucirumab plus nivolumab in patients with previously treated advanced gastric adenocarcinoma

Researchers

Presenter

  • H.Shoji

Principal Investigators

  • H.Miyamoto

  • H.Hara

  • D.Takahari

  • N.Machida

  • T.Esaki

  • K.Nagashima

  • K.Aoki

  • K.Honda

  • Y.Nagata

  • T.Miyamoto

  • N.Boku

  • K.Kato

Medical Centers

  • Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan

  • FIVERINGS CO., LTD., Osaka, Japan

  • Department of Gastroenterology, Chiba Cancer Center, Chiba, Japan

  • Department of Pharmacy,The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

  • Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Japan, Shizuoka, Japan

  • Department of Gastrointestinal and Medical Oncology, National Kyushu Cancer Center, Fukuoka, Japan

  • Department of Global Clinical Research, Graduate School of Medicine, Chiba University, Chiba, Japan

  • Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo, Japan

  • Division of Chemotherapy and Clinical Research, National Cancer Center Research Institute, Tokyo, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

  • Programmed cell death protein 1

  • Programmed death-ligand 1

  • Kinase Insert Domain Receptor

Drug/Treatment

  • Ramucirumab

  • Paclitaxel

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • NCT02999295

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved